Vasotop R tablets 1, 25mg

DESCRIPTION

Vasotop R is a drug for the treatment and prevention of chronic heart failure in dogs and the control of blood pressure in cats. Dosage form: tablets for oral administration.

COMPOSITION

Each tablet of Vasotop R contains as an active ingredient: ramipril - 1.25 mg. The drug in one tablet contains as auxiliary components 0.221 mg of hypromellose, 44.529 mg of pregelatinized starch, 42.5 mg of microcrystalline cellulose, 10 mg of powdered beef flavor, 0.50 mg of sodium stearyl fumarate, 0.50 mg of colloidal silicon oxide anhydride, 0.50 mg.

PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: angiotensin converting enzyme (ACE) inhibitor.

Ramipril, which is part of Vasotope R, is an antihypertensive agent that, by suppressing the synthesis of antihyotensin II, reduces its vasoconstrictor effect and its stimulating effect on aldosterone secretion, and also inhibits the breakdown of bradykinin. Vasotope P reduces the total vascular peripheral resistance, does not significantly alter renal blood flow (and in some cases increases it) and glomerular filtration rate. Vasotope P has a hypotensive effect without causing compensatory tachycardia. After a single dose of Vasotope R, the hypotensive effect reaches a maximum in 1-3 hours. And it continues for 24 hours. With daily intake of Vasotope R, the hypotensive effect gradually increases over 3-4 weeks and remains at this level during the treatment period.

Vasotop P also has a cardioprotective effect by inhibiting the angiotensin-converting enzyme in the myocardium and accumulating bradykinin.

After oral administration of Vasotope R, ramipril is rapidly absorbed in an amount of at least 50-60% of the dose taken. The primary metabolism of ramipril occurs in the liver. This forms a pharmacologically active derivative of ramipril - ramiprilat. Ramiprilat is 6 times more active than ramipril in inhibiting angiotensin-converting enzyme. Plasma protein binding for ramipril is 73%, and for ramiprilat - 56%.

With a single daily intake of Vasotope R, a stable concentration of ramiprilat in plasma is achieved by the 4th day. In dogs, about 60% of the drug is excreted in the urine and about 40% in the faeces (mainly in the form of metabolites).

In cats, ramipril is excreted mainly in feces (from 85% to 89%) and to a lesser extent in urine (9% to 12%).

In case of impaired renal function, the excretion of ramipril and its metabolites slows down in proportion to the decrease in creatinine clearance.

By the degree of impact on the body, Vasotop R belongs to the group of low-hazard substances (hazard class 4 according to GOST 12.1.007-76).

INDICATIONS

Vasotop R is used in dogs with chronic heart failure, arterial hypertension, cardiomyopathies of various origins and for the prevention of myocardial ischemia.

Cats are used to lower systolic blood pressure (if the systolic pressure is between 160 and 230 mm Hg).

APPLICATION

The drug is administered orally 1 time per day, on an empty stomach. The initial therapeutic dose is 0.125 mg of the active ingredient ramipril per 1 kg of animal weight. Large dogs (weight over 50 kg) can be given a daily dose of the drug in two doses. The animal must be accurately weighed before calculating the dose.

If there is no effect against the background of taking Vasotope R, the daily dose can be increased to 0.25 mg / kg of animal weight and / or diuretic drugs can be included in the treatment regimen in conventional doses to enhance the therapeutic effect.

In case of congestion in the lungs, two weeks after starting the use of the drug, the daily dose can be increased to 0.25 mg per 1 kg of animal weight.

Vasotope P is prescribed for cats if the cause of the increase in blood pressure cannot be eliminated (for example, hyperthyroidism). Treatment with Vasotop R should be carried out under regular supervision of a veterinarian (1 time in 7-14 days).

In cats with severe eye damage or rapidly progressive neurological symptoms (due to increased blood pressure), a clinical assessment is recommended every 1 to 2 days.

The duration of treatment with Vasotop R is determined by the veterinarian.

SPECIAL INSTRUCTIONS

Animals that have an increased risk of developing excessive hypotension after taking the first dose, as well as after increasing the dose of the drug, should be under the strict supervision of a veterinarian, especially in the first 2 weeks of treatment. In the case of hypotension, ataxia, tachycardia, arrhythmias and angina pectoris, treatment with Vasotop R should be discontinued. Diuretics and a diet with a low salt content enhance the effect of the drug, therefore, in order to avoid the development of severe hypotension, accompanied by apathy, ataxia, fainting or acute renal failure, the dose of these drugs should not be exceeded. Simultaneous use with potassium-containing drugs is not recommended, as this can lead to the development of hyperkalemia in the body.

CONTRAINDICATIONS

Increased individual sensitivity to the components of the drug, decompensated hepatic and renal failure, as well as lactation and pregnancy of animals. The drug is not used in dogs for mitral valve stenosis, aortic stenosis and obstructive hypertrophic cardiomyopathy.

SIDE EFFECTS

In some cases, the animal may experience the following side effects while using the drug: from the respiratory system - sinusitis, rhinitis, bronchospasm; from the gastrointestinal tract - nausea, dyspepsia, vomiting, diarrhea, constipation, dysphagia, loss of appetite; from the nervous system - convulsions, neuralgia, neuropathy, paresthesia, tremor. If a side effect occurs, the use of Vasotope R should be discontinued and a veterinarian should be consulted.

STORAGE

Store in a dry, dark place and out of reach of children and animals, separately from food and feed at a temperature of 2 В° C to 30 В° C. Shelf life, subject to storage conditions, is 3 years from the date of production.

PACKING

The tablets are packed in plastic bottles of 28 pcs. The package contains 3 bottles.

Specifications

KolVUP

1

Manufacturer

Intervet

Temperature regime

from +2 to +25

Teaser

an antihypertensive drug for the treatment and prevention of chronic heart failure in dogs